Mannkind reports net loss for second quarter
Mannkind reported $2.16 million in revenues Aug. 7, for a net loss of around $35.3 million for its second quarter, and announced the launch of a clinical trial for its inhalable insulin product Afrezza in partnership with One Drop. Revenues came primarily from the Westlake Village biotech company’s product sales, with $615,000 from collaborations and Read More →
Read More →
Sienna stock still soaring after $65 million IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →PennyMac reports decline in net income
Westlake Village-based PennyMac Mortgage Investment Trust and PennyMac Financial Services reported a drop in earnings on Aug. 3 for the quarter ended June 30. Investment income was up 30 percent compared to the prior quarter, but net income for the mortgage investment trust was $26.4 million, a 6 percent decline from the same period in Read More →
Read More →Sienna stock soars after $65 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals closed with a big gain after it raised $65 million in its initial public offering July 27. Sienna priced the 4.33 million shares it offered at $15. Shares had reached $21 around noon before ending at $19.25, a 28.3 percent premium on its opening price. The company operates in Read More →
Read More →Dole supplier awarded Rainforest Alliance certification
Dole Food supplier Huelquen Farms, in Paine, Chile, achieved the Rainforest Alliance certification, the company announced July 26. The farm grows 100 hectares, or around 247 acres, of table grapes under the Westlake Village-based Dole Food label and was successfully audited to the Sustainable Agriculture Network Standard. The Rainforest Alliance is an international nonprofit organization Read More →
Read More →Sienna Biopharmaceuticals files for $75 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals filed for an initial public offering with the Securities and Exchange Commission on June 3, stating expectations to raise up to $74.75 million. Founded in 2010, the company develops clinical-stage topical therapies for inflammatory skin diseases and other conditions. ARCH Venture Partners and Venvest Capital led a $40 million Read More →
Read More →Coding Autism wins MIT entrepreneurial competition
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
